Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR)

Clinical and Experimental Metastasis

Volumn 17, Issue 3, 1999, Pages 255-263

  Webber, Mukta M ^a   Bello DeOcampo, Diana ^a   Quader, Salmaan ^a   Deocampo, Nestor D ^a   Metcalfe, W Scott ^a   Sharp, Rebekah M ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

4 HPR; Apoptosis; Invasion; Prostate cancer; Retinoid receptors; Vimentin

Indexed keywords

FENRETINIDE; RETINOIC ACID; RETINOID X RECEPTOR; VIMENTIN;

APOPTOSIS; ARTICLE; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MALE; PHENOTYPE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA; CELL DIVISION; CELL MOVEMENT; EPITHELIAL CELLS; FENRETINIDE; HUMANS; MALE; NEOPLASM INVASIVENESS; PHENOTYPE; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; TUMOR CELLS, CULTURED; UP-REGULATION; VIMENTIN;

EID: 0032787840     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006665616932     Document Type: Article

References (47)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics. Cancer J Clin 1998; 48: 6-29.
2. Bostwick DG, Foster CS. Examination of radical prostatectomy specimens: Therapeutic and prognostic significance, In: Foster CS, Bostwick DG, (eds) Pathology of the Prostate, pp. 172-89. Philadelphia, Saunders, 1998.
3. Hong WK, Sporn MB. Recent advances in chemoprevention of Cancer. Science 1997; 278: 1073-77.
4. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150: 379-85.
5. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate 1990; 16: 39-48.
6. Webber MM, Bello D, Kleinman HK, Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 1997; 18: 1225-31.
7. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Part 3. Oncogenes, suppressor Genes, and applications. Prostate 1997; 30: 136-42.
8. Webber MM, Waghray A, Bello D, Rhim JS. Mini Review: Proteases and invasion in human prostate epithelial cell lines: Implications in prostate cancer prevention and intervention. Radial Oncol Invest 1996; 3: 358-62.
9. Hong WK, Lippman SM, Hittelman WN, Lotan R. Retinoid chemoprevention of acrodigestive Cancer: From basic research to the clinic. Clin Cancer Res 1995; 1: 677-86.
10. Meyskens FL Jr, Surwit E, Moon TE, Childers JM, Davis JR, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J Natl Cancer Inst 1994; 86: 539-43.
11. Webber MM, Waghray A. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin Cancer Res 1995; 1: 755-61.
12. Hendrix MJC, Seftor EA, Seftor REB, Trevor KT. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 1997; 150: 483-95.
13. Sommers CL, Skerker JM, Chrysogelos SA, Bosseler M, Gelmann EP. Regulation of vimentin gene transcription in human breast cancer cell lines. Cell Growth & Differ 1994; 5: 839-46.
14. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997; 18: 1215-23.
15. de -Feijter AW, Matesic DF, Ruch RJ, Guan X, Chang CC, Trosko JE. Localization and function of the connexin 43 gap-junction protein in normal and various oncogene-expressing rat liver epithelial cells. Mol Carcinog 1996; 16: 203-12.
16. Pellegrini R, Mariotti A, Tagliahue E, Bressan R, Bunone G, et al. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth & Differ 1995; 6: 863-69.
17. Wang TTY, Phang JM. Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett 1996; 107: 65-71.
18. Igawa M, Tanabe T, Chodak GW, Rukstalis DB. N-(4-hydroxyphenyl)retinamide induces cell cycle specific growth inhibition in PC3 cells. Prostate 1994; 24: 299-305.
19. Pienta KJ, Nguyen NM, Lehr JE. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 1993; 53: 224-6.
20. Pollard M, Luckert PH, Sporn M. Prevention of primary prostate cancer in Lobund Wistar Rats by N-(4-hydroxyphenyl)retinamide. Cancer Res 1991; 51: 3610-11.
21. Lucia MS, Anzano MA, Slayter MV, Anver MR, Green DM, et al. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D Analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res; 1995; 55: 5621-27.
22. Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, et al. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras4 myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 1993; 53: 4461-5.
23. Grandis JR, Zeng Q, Tweardy DJ. Retinoic acid normalizes the increased gene transcription rate of TGF α and EGFR in head and neck cancer cell lines. Nature Med 1996; 2: 237-40.
24. Gotz W, Kasper M, Fischer G, Herken R. Intermediate filament typing of the human embryonic and fetal notochord. Cell Tissue Res 1995; 280: 455-62.
25. Klundert van de FAJM, Jansen HJ, Bloemendal H. Negative regulation of a special, double AP-1 consensus element in the vimentin promoter: Interference by the retinoic acid receptor. J Cell Physiol 1995; 164: 85-92.
26. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 1994; 31: 325-35.
27. Heatly M, White J, Patterson A, Maxwell P, Whiteside C, Toner P. Intermediate filament expression of ductal carcinoma cells in fine needle aspirates of the breast. Acta Cytol 1997; 41: 717-20.
28. Takahashi N, Breitman TR. Unassembled (soluble) vimentin in human myeloid leukemia cell line HL60. Eur J Haematol 1994; 53: 78-84.
29. Takeda M, Nishimura T, Hariguchi S, Tatebayashi Y, Tanaka T, Tanimukai S, Tada K. Study of cytoskeletal proteins in fibroblasts cultured from familial Alzheimer's disease. Acta Neurol Scand 1991; 84: 416-20.
30. Fraga CH, True LD, Kirk D. Enhanced expression of the mesenchymal marker, vimentin, in hyperplastic versus normal human prostatic epithelium. J Urol 1998; 159: 270-74.
31. Wernert N, Seitz G. Immunohistochemical Investigation of different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma. Pathol Res Pract 1987; 182: 617-26.
32. Mostofi FK, Sesterhenn IA, Davis CJ Jr. Prostatic Intraepithelial neoplasia (PIN): Morphological clinical significance. Prostate 1992; 4 (suppl): 71-7.
33. Battifora H. Assessment of antigen damage in immunohistochemistry: The vimentin internal control. Am J Clin Pathol 1991; 96: 669-71.
34. Nagle RB, Brawer MK, Kittelson J, Clark V. Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am J Pathol 1991; 138: 119-28.
35. Bussemakers MJG, Verhaegh GWCT, van Bokhoven A, Debruyne FMJ, Schalken JA. Differential expression of vimentin in rat prostatic tumors. Biochem Biophys Res Commun 1992; 182: 1254-59.
36. Webber MM, Waghray A, Bello D. Prostate-specific antigen, aserine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995; 1: 1089-94.
37. Dahiya R, Park HD, Cusick J, Vessella RL, Fournier G, Narayan P. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 1994; 59: 126-32.
38. Lotan R. Retinoids and Apoptosis: Implications for cancer chemoprevention and therapy. J Natl Cancer Inst 1995; 87: 1655-57.
39. Oridate N, Lotan D, Mitchell MF, Hong WK, Lotan R. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: Implications for chemoprevention. J Cell Biochem (suppl) 1995: 23: 80-6.
40. Hsieh TC, Wu JM. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression. Prostate 1997; 33: 97-104.
41. Roberson KM, Penland SN, Padilla GM, Selvan RS, Kim CS, et al. Fenretinide: Induction of apoptosis and endogenous transforming growth factor β in PC-3 prostate cancer cells. Cell Growth & Differ 1997; 8: 101-11.
42. Widschwendter M, Daxenbichler G, Culig Z, Michel S, Zaimet AG, et al. Activity of retinoic acid receptor-γ selectively binding retinoids alone and in combination with interferon-γ in breast cancer cell lines. Int J Cancer 1997; 71: 497-504.
43. Meister B, Fink FM, Hittmair A, Marth C, Widschwendter M. Antiproliferative activity and apoptosis induced by retinoic acid receptor-γ selectively binding retinoids in neuroblastoma. Anticancer Res 1998; 18: 1777-86.
44. Toma S, Isnardi L, Riccardi L, Bollag W. Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res 1998; 18: 935-42.
45. Fanjul AN, Domenico D, Pierotti MA, Rideout D. Qiu J, Pfahl M. 4-Hydroxyphenyl-retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996; 271: 22441-46.
46. McCormick DL, Rao KVN, Dooley L, Steele VE, Lubet RA, et al. Influence of N-methyl-N-nitrosourca, teslosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction on Wistar-Unilever Rats. Cancer Res 1998; 58: 3282-88.
47. Tradati N, Chiesa F, Rossi N, Grigolato R, Formelli F, et al. Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett 1994; 76: 109-11.